MoonLake Immunotherapeutics (MLTX) grants CEO 520,342 stock options

Rhea-AI Filing Summary

MoonLake Immunotherapeutics reported that Chief Executive Officer and director Jorge Santos da Silva received a new stock option award. On January 7, 2026, he was granted an option to buy 520,342 Class A ordinary shares at an exercise price of $11.29 per share. The option runs until January 7, 2036.

These options vest over time, rather than all at once. The award vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, and each vesting installment requires his continued service with the company through the relevant date. The filing shows he holds these derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos da Silva Jorge

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.29	01/07/2026		A		520,342		(1)	01/07/2036	Class A ordinary shares, par value $0.0001 per share	520,342	$0	520,342	D

Explanation of Responses:

1. This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report on this Form 4?

The company reported that Chief Executive Officer and director Jorge Santos da Silva received a stock option grant. The option gives him the right to buy 520,342 Class A ordinary shares of MoonLake Immunotherapeutics.

How many stock options did the MoonLake (MLTX) CEO receive and at what exercise price?

The CEO received an option covering 520,342 Class A ordinary shares. The option has an exercise price of $11.29 per share.

What is the vesting schedule for the MoonLake (MLTX) CEO’s new stock options?

The option vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030. Each installment requires the CEO to continue serving the company through the applicable vesting date.

When do the newly granted MoonLake (MLTX) stock options expire?

The stock option granted to the CEO on January 7, 2026 has an expiration date of January 7, 2036, giving a 10-year term from the grant date.

Are the MoonLake (MLTX) CEO stock options held directly or indirectly?

The filing shows that the 520,342 stock options are held under direct ownership by the reporting person, Jorge Santos da Silva.

What type of security is reported in this MoonLake (MLTX) Form 4?

The reported security is a stock option (right to buy), which is a derivative security that can be exercised to purchase Class A ordinary shares at a fixed price of $11.29 per share.